LLY

1,058.52

+2.3%↑

JNJ

233.75

+2.08%↑

ABBV

218.03

+2.36%↑

UNH

388.26

+1.41%↑

AZN

187.06

-0.15%↓

LLY

1,058.52

+2.3%↑

JNJ

233.75

+2.08%↑

ABBV

218.03

+2.36%↑

UNH

388.26

+1.41%↑

AZN

187.06

-0.15%↓

LLY

1,058.52

+2.3%↑

JNJ

233.75

+2.08%↑

ABBV

218.03

+2.36%↑

UNH

388.26

+1.41%↑

AZN

187.06

-0.15%↓

LLY

1,058.52

+2.3%↑

JNJ

233.75

+2.08%↑

ABBV

218.03

+2.36%↑

UNH

388.26

+1.41%↑

AZN

187.06

-0.15%↓

LLY

1,058.52

+2.3%↑

JNJ

233.75

+2.08%↑

ABBV

218.03

+2.36%↑

UNH

388.26

+1.41%↑

AZN

187.06

-0.15%↓

Kodu・Aktsiate loetelu・Simulations Plus Inc

Simulations Plus Inc

Suletud

SektorTervishoid

15.14 4.78

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.88

Max

15.26

Põhinäitajad
By Trading Economics
Sissetulek	3.9M 4.5M
Müük	5.9M 24M
Aktsiakasum	0.35
Dividenditootlus	0.48
Kasumimarginaal	18.669
Töötajad	212
EBITDA	4.9M 7.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+10.57% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.48% 2.39%
Järgmine tulemuste avaldamine	13. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	27M 278M
Eelmine avamishind	10.36
Eelmine sulgemishind	15.14

Uudiste sentiment

By Acuity

56%

44%

280 / 345 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. mai 2026, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21. mai 2026, 16:49 UTC

Tulu

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21. mai 2026, 16:26 UTC

Suurimad hinnamuutused turgudel

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21. mai 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21. mai 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21. mai 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21. mai 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21. mai 2026, 22:33 UTC

Omandamised, ülevõtmised, äriostud

Conduent to Sell Public Transit Business to Modaxo for $164M

21. mai 2026, 21:53 UTC

Tulu

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21. mai 2026, 21:02 UTC

Tulu

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21. mai 2026, 20:55 UTC

Tulu

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21. mai 2026, 20:30 UTC

Kuumad aktsiad

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21. mai 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. mai 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21. mai 2026, 20:20 UTC

Tulu

Webull 1Q Adj EPS 3c >BULL

21. mai 2026, 20:20 UTC

Tulu

Webull 1Q Rev $159.9M >BULL

21. mai 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21. mai 2026, 20:18 UTC

Tulu

Webull 1Q Loss/Shr 4c

21. mai 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21. mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21. mai 2026, 18:58 UTC

Tulu

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21. mai 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21. mai 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21. mai 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21. mai 2026, 17:01 UTC

Tulu

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21. mai 2026, 16:20 UTC

Market Talk

Tulu

Stellantis Targets Distant but Constructive -- Market Talk

21. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

10.57% tõus

12 kuu keskmine prognoos

Keskmine 16 USD 10.57%

Kõrge 16 USD

Madal 16 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Simulations Plus Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

280 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.